TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Gelatine Solutions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* Male or female patients \>= 18 years of age and \<= 90 years of age. Women of child bearing potential must test negative on standard pregnancy test.~* Patients scheduled to undergo elective abdominal surgery (e.g. Rectal resection, liver resection, open bowl resection, duodenopancreatectomy reconstitution).~* Scheduled intraoperative volume requirement of at least 15 ml / kg body weight (BROCA) gelatine solution~* Provision of voluntary consent to participate in the study, following a full explanation of the nature and purpose of the study, by signing the informed consent form approved by the Institutional Ethics Committee (IEC) prior to all evaluations.~Exclusion:~* Patients of ASA-class \> III~* Known hypersensitivity to gelatine or to any of the constituents of the solution~* Patients treated with other colloid solutions and / or blood products 24 hours prior to surgery~* Patients on hemodialysis~* Patients suffering from decompensated renal function (i.e. serum creatinine \> 3.0 mg/dl)~* Patients suffering from Hypervolemia Hyperhydration Severe blood coagulation disorders Hypernatremia (serum(Na+) \> 150 mmol/L) Hyperchloremia (serum(Cl-) \> 110 mmol/L)~* Estimated perioperative need for blood products of 3,5 ml / kg body weight (BROCA)~* Lactation period~* Simultaneous participation in another clinical trial~* Emergencies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- balanced gelatine solution (Type: EXPERIMENTAL): isotonic colloidal volume substitute
- non-balanced gelatine solution (Type: ACTIVE_COMPARATOR): colloidal volume substitute

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nitazoxanide for the Treatment of Prolonged Diarrhea in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with diarrhea ≥3 days but \<30 days duration.~* No visible blood in stool.~Exclusion Criteria:~* Use of any antibacterial, antiparasitic or antiviral drugs within 5 days of enrollment.~* Females who are pregnant, suspected of being pregnant or breastfeeding.~* Serious systemic disorders incompatible with the study.~* History of hypersensitivity to nitazoxanide.~* Patients in whom the possibility of receiving placebo and not being able to receive immediately an effective treatment will be incompatible with the severity of the patient's illness according to the investigator's judgment.~* Patients known to have or suspected of having AIDS or other immune deficiencies.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Nitazoxanide Suspension (Type: EXPERIMENTAL): Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years
- Placebo Suspension (Type: PLACEBO_COMPARATOR): Placebo Oral Suspension 5 ml for patients aged 1-3 years and Placebo Oral Suspension 10 ml for patients aged 4-11 years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antipsychotic Therapy and First Episode

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients, from 18 to 65 years of age at Visit 1~* Patients must achieve a level of understanding and expressive capacity sufficient to communicate adequately with the study coordinator and to participate in cognitive testing.~* Patients must agree to cooperate with all tests and examinations required by the protocol. They must be willing to comply fully with treatment~* Patient must understand the nature of the study and must sign an informed consent document.~* Patients must be Cantonese speaking Han Chinese~* Patients must be diagnosed, according to the SCID for DSM-IV, with schizophrenia, schizoaffective disorder or schizophreniform psychosis.~* Patients must have good response to anti-psychotic treatment by achieving a rating of 2 or below in Clinical Global Impression Scale (CGI) Severity of illness; a rating of 4 or below in Improvement scale, and a rating of 3 or below in (conceptual disorganization, unusual thought content), a rating of 2 or below in (delusion, hallucinatory behavior) and a rating of 4 or below in (Suspiciousness) of Positive and Negative Syndrome Scale (PANSS) for at least 8 weeks~Exclusion Criteria:~* Female patients who are either pregnant or lactating.~* Patients previously on clozapine should be excluded from the study~* Significant medical illnesses including seizures.~* DSM-IV substance (alcohol or other drugs) abuse or dependence within the past 3 months.~* Judged clinically to be at serious suicidal risk.~* Treatment with an injectable depot neuroleptic within less than one of the patient's dosing intervals between depot neuroleptic injections prior to study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Peripheral Nerve Injury~Exclusion Criteria:~* Peripheral Neuropathy~* Allergic to Bovine products such as Bovine Collagen Nerve Cuff

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Processed Nerve Allograft (Type: EXPERIMENTAL): Processed Nerve Allograft
- Collagen Nerve Cuff (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Be a healthy, adult male and/or female volunteer 18 to 40 years of age with no past or present history of any significant disease based on PI discretion;~2. If female, must be post-menopausal, surgically sterile, or using effective birth control methods with a negative urine pregnancy test at the Screening and Baseline visits (female subjects of childbearing potential only);~3. Show a high degree of fluorescence of the face under a Wood's lamp at the screening visit.~4. Be willing to refrain from using antimicrobial topical products for the duration of study participation;~5. Be willing to return to the study center for all study visits;~6. Be willing to follow all study instructions and adhere to study restrictions;~7. Provide informed consent to the study procedures and restrictions~Exclusion Criteria:~1. Have a history of skin disease or presence of skin condition the PI believes would interfere with the study;~2. Females who report that they are pregnant, planning a pregnancy or breastfeeding or those females who are of child bearing potential, that test positive with a urine pregnancy test;~3. Have conditions or factors that the PI believes may affect the response of the skin or the interpretation of the results;~4. Participated in any clinical study within the previous 30 days, be concurrently participating in other studies, or be involved in any aspect of test administration;~5. Use of topical or systemic antibiotics or other products within the previous 4 weeks prior to baseline, that influence P. acnes counts;~6. Are known to be allergic to any of the test product(s) or any components in the test product(s);~7. Have a history of significant medical condition/disease that the PI believes may affect the response of the skin or the interpretation of the results;~8. Has any other condition that, in the opinion of the Investigator or his designee, could interfere with the subject's ability to use the treatment as instructed, alter their treatment response, or affect their ability to complete the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- BPX-01, 1% Topical Gel (Type: EXPERIMENTAL): BPX-01, 1% Topical Gel; applied once daily to the face for four weeks.
- BPX-01, Vehicle Gel (Type: PLACEBO_COMPARATOR): BPX-01, Vehicle Gel; applied once daily to the face for four weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged \>= 6 months to \< 9 years at the time of the first study vaccination.~* For children \< 3 years of age at the time of first vaccination, born at or after 36 weeks of gestation.~Exclusion Criteria:~* Known hypersensitivity to a previous dose of influenza virus vaccine or allergy to eggs, chicken protein, thiomersal, neomycin, polymyxin, or any components of the Study Vaccine.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 8 Years
- Healthy Volunteers: t

Study Arms:
- CSL425 (15 mcg) (Type: EXPERIMENTAL): 15 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
- CSL425 (30 mcg) (Type: EXPERIMENTAL): 30 mcg of hemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Artemether/Lumefantrine and Vivax Malaria

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with vivax malaria~Exclusion Criteria:~* severe malaria~* pregnancy

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- artemether-lumefantrine (Type: EXPERIMENTAL): tablets (containing 20mg artemether and 120 mg lumefantrine) for three days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Effective Contraceptive Use Among Opioid-maintained Women: Stage II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18-44 years of age~* pre-menopausal and have no history of tubal ligation or hysterectomy~* have had heterosexual vaginal sex in the past 3 months~* have no plans to become pregnant in the next 6 months~* be medically eligible to use prescription contraceptives~* report no prescription contraceptive use (i.e., no use of pill, patch, ring, implants, or IUDs in the past 7 days or injections in the past 3 months)~* be in opioid maintenance treatment~* at least 8 weeks postpartum~* not be facing imminent incarceration~* have no plans to leave the area in the next 12 months~* be English-speaking~Exclusion Criteria:~* failure to meet the aforementioned inclusion criteria~* refusal to participate

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 44 Years
- Healthy Volunteers: f

Study Arms:
- Treatment as usual (Type: ACTIVE_COMPARATOR): The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
- WHO contraception protocol (Type: EXPERIMENTAL): The WHO contraception protocol condition will receive the World Health Organization's contraception protocol and will be invited to attend follow-up visits.
- WHO contraception protocol + incentives (Type: EXPERIMENTAL): The WHO + incentives condition will receive the World Health Organization's contraception protocol and will be invited to attend follow-up visits, but will also receive financial incentives contingent on attending those follow-up visits.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females ≥ 12 to ≤ 80 years of age~* Diagnosis of homozygous familial hypercholesterolemia~* Stable lipid-lowering therapies for at least 4 weeks~* LDL cholesterol ≥ 130 mg/dl (3.4 mmol/L)~* Triglyceride ≤ 400 mg/dL (4.5 mmol/L)~* Bodyweight of ≥ 40 kg at screening.~Exclusion Criteria:~* LDL or plasma apheresis within 8 weeks prior to randomization~* New York Heart Association (NYHA) class III or IV or last known left ventricular ejection fraction \< 30%~* Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months of randomization~* Planned cardiac surgery or revascularization~* Uncontrolled cardiac arrhythmia~* Uncontrolled hypertension

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Part A: Evolocumab (Type: EXPERIMENTAL): Participants received open-label evolocumab 420 mg subcutaneously once a month for 12 weeks.
- Part B: Evolocumab (Type: EXPERIMENTAL): Participants received double-blind evolocumab 420 mg subcutaneously once a month for 12 weeks.
- Part B: Placebo (Type: PLACEBO_COMPARATOR): Participants received double-blind placebo subcutaneously once a month for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes Mellitus (T2DM)~* Currently being treated with diet/exercise and on stable dose of sitagliptin for ≥ 4 weeks, on any additional oral hypoglycemic agent (AHA) in the prior 8 weeks, and HbA1c ≥ 6.0% and ≤ 9.0%; or~* Currently being treated with diet/exercise and on stable dose of sitagliptin for ≥ 10 weeks, not on any additional oral AHA in the prior 8 weeks, and HbA1c ≥ 6.5% and \< 10.0%~Exclusion Criteria:~* Type 1 diabetes mellitus,~* Secondary diabetes mellitus, or~* Gestational diabetes mellitus

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Metformin 500 mg q.d. (Type: EXPERIMENTAL): Participants will receive sitagliptin daily (continuing their pre-study dose), 2 metformin 250 mg tablets in the morning and 1 matching placebo tablet in the evening.
- Metformin 250 mg b.i.d. (Type: EXPERIMENTAL): Participants will receive sitagliptin daily (continuing their pre-study dose), 1 metformin 250 mg tablet and 1 matching placebo tablet in the morning and 1 metformin 250 mg tablet in the evening.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive sitagliptin daily (continuing their pre-study dose), 2 matching placebo tablets in the morning and 1 matching placebo tablet in the evening.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug-Drug Interaction Study Between Colchicine and Cyclosporine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults 18-45 years of age, non-smoking and non-pregnant (post-menopausal, surgically sterile or using effective contraceptive measures) with a body mass index (BMI) greater than or equal to 18 and less than or equal to 32, inclusive.~Exclusion Criteria:~* Recent participation (within 28 days) in other research studies~* Recent significant blood donation or plasma donation~* Pregnant or lactating~* Test positive at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV)~* Recent (2-year) history or evidence of alcoholism or drug abuse~* History or presence of significant cardiovascular, pulmonary, hepatic, gallbladder or biliary tract, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease~* Subjects who have used any drugs or substances known to inhibit or induce cytochrome (CYP) P450 enzymes and/or P-glycoprotein (P-gp) within 28 days prior to the first dose and throughout the study~* Drug allergies to colchicine or cyclosporine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Colchicine alone (Type: ACTIVE_COMPARATOR): -baseline colchicine pharmacokinetics
- Colchicine with Cyclosporine (Type: EXPERIMENTAL): -colchicine pharmacokinetics in presence of cyclosporine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of CF documented by sweat chloride results (\>60 mmol/L) and require pancreatic enzyme replacement therapy (PERT) to control clinical symptoms of EPI (nausea, vomiting, bloating, diarrhea, and abdominal pain) with a history of excess fat in the feces~* Have documentation of an abnormal COA-fat and a fecal elastase result of \<100 micrograms fecal elastase/gram stool~* Must be on a stable diet and dose of pancreatic enzyme supplementation that has provided satisfactory symptom control for at least the past 1 month~Exclusion Criteria:~* No extreme physical wasting with loss of weight and muscle mass~* No severe, acute, or chronic pulmonary disease unrelated to complications of CF~* No worsening of pulmonary disease in past 30 days~* No use of drugs known to affect blood uric acid concentrations (e.g., aspirin, diflunisal, allopurinol, probenecid, thiazide diuretics, phenylbutazone, sulfinpyrazone)~* No known congenital (present at birth) abnormalities of the gastrointestinal tract, heart, or liver~* No distal intestinal obstruction syndrome (DIOS)

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Pancrease MT 10.5 or MT 21 Pancrease MT capsules for maximum dose of 10 000 lipase units / Kg / day
- 002 (Type: EXPERIMENTAL): Placebo for Pancrease MT 10.5 or MT 21 Capsules with Pancrease MT excipients without the active enzymes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Proven disease,~* No betablocker at inclusion if previous CV event~Exclusion criteria:~Criteria of not inclusion for the RIGHTEOUS group:~* Patient having already presented an arterial break or a dissection and treated(handled) by bétâ-blocking(surrounding).~* Against indication in the use of CELIPROLOL:~* Unchecked cardiac insufficiency by the treatment~* cardiogenic shock~* BAV of 2nd and 3rd not sailed degrees~* angor of Prinzmetal~* disease of the sine~* bradycardia~* pheochromocytoma untreated~* low blood pressure~* sentimentality in the CELIPROLOL~* Antecedent of anaphylactic reaction~* myasthenia~* treatment by FLOCTAFENINE ( Idarac), Sultopride ( interactions ) In these two cases, the patient can be included in the group followed by troop.~Criteria of not inclusion for both groups:~* Refusal to participate in the study.~* Impossibility to move.~* Pregnancy~* Woman in age to procreate without means of effective contraception.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Celiprolol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete